Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis

Documenti analoghi

• Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
  di: de Vlam, K, et al.
  Pubblicazione: (2018)
• Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
  di: de Vlam, K, et al.
  Pubblicazione: (2021)
• Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
  di: Taylor, P, et al.
  Pubblicazione: (2019)
• Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
  di: de Vlam, K, et al.
  Pubblicazione: (2022)
• Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
  di: Taylor, PC, et al.
  Pubblicazione: (2020)